Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12 at 4:20 p.m. PT / 7:20 p.m. ET in Las Vegas, Nevada.

A live webcast of the fireside chat will be available at https://investors.vir.bio and will be archived for 30 days.

About Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

Vir Biotechnology retains exclusive rights to the PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260505403526/en/

Media Contact
Caren Scannell
Director, Communications
[email protected]

Investor Contact
Kiki Patel, PharmD
Head of Investor Relations
[email protected]

Source: Vir Biotechnology

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Buy gold stocks as valuations are cheap amid macro tension: BofA
• Danske Bank A/S, transactions by persons discharging managerial responsibilities